Gilead Sciences is a biopharmaceutical company that researches, develops, and commercializes medicines. Gilead’s Veklury (remdesivir) was one of the first antiviral treatments authorized for COVID-19. Gilead also pioneered groundbreaking treatments for HIV that helped transform the fatal virus into a manageable chronic condition. The company continues to expand into oncology and other chronic conditions through acquisitions, such as CymaBay, which developed a treatment for a rare liver disease.
David Paul Morris—Bloomberg/Getty Images
Change the World 2025
Gilead’s drugs have helped change HIV infection from a death sentence to a manageable condition. In 2012, it launched the first pre-exposure prophylaxis (PrEP) preventive drug for HIV. In June, it won FDA approval for Yeztugo, a PrEP drug requiring only two doses a year—giving it far greater potential efficacy in preventing new infections.
